Pretreatment with granulocyte-colony stimulating factor decreases lipopolysaccharide-induced interferon-γ production in mice in association with the production of interleukin-18

被引:7
作者
Christine, CL
Guo, J
Faggioni, R
Fantuzzi, G
Senaldi, G
机构
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
[2] Univ Colorado, Hlth Sci Ctr, Div Infect Dis, Denver, CO USA
关键词
G-CSF; IFN-gamma; IL-18; LPS; neutrophils;
D O I
10.1016/j.cyto.2003.10.007
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We studied the effects of pretreatment with granulocyte-colony stimulating factor (G-CSF) on the production of pro- and anti-inflammatory cytokines induced by lipopolysaccharide (LPS). Mice received G-CSF or control saline once a day for 7 days or once at 1 h before the injection of LPS. Cytokines were measured by enzyme-linked immunosorbent assay or antibody-based electrochemiluminescence assay and cytokine mRNA was measured by RNAse protection assay. Mice pretreated with G-CSF for 7 days before LPS had lower serum levels of LPS-induced interferon-gamma (IFN-gamma) and higher levels of interleukin (IL)-6 and IL-10 than controls. G-CSF-pretreated mice also had lower mRNA levels of IFN-gamma and higher mRNA levels of IL-6 and IL-10 in the spleen and/or liver than controls. G-CSF-pretreated mice had serum levels of tumor necrosis factor, IL-12 p70 and IL-12 p40 similar to controls. G-CSF-pretreated mice had lower levels of spleen IL-18 than controls-serum IL-18 being undetectable in mice after LPS- and lower levels of IL-18 mRNA in the spleen. Mice pretreated with G-CSF I h before LPS had lower levels of serum IFN-gamma and spleen IL-18 than controls. G-CSF pretreatment alters the expression of LPS-induced cytokines with a decrease in proinflammatory IFN-gamma and an increase in anti-inflammatory IL-6 and IL-10. G-CSF decrease of IL-18 production may be a major mechanism explaining the effects of G-CSF on the production of IFN-gamma. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:119 / 126
页数:8
相关论文
共 47 条
[1]  
ADERKA D, 1989, J IMMUNOL, V143, P3517
[2]   PROTECTIVE ROLE OF INTERLEUKIN-6 IN THE LIPOPOLYSACCHARIDE-GALACTOSAMINE SEPTIC SHOCK MODEL [J].
BARTON, BE ;
JACKSON, JV .
INFECTION AND IMMUNITY, 1993, 61 (04) :1496-1499
[3]   PASSIVE-IMMUNIZATION AGAINST CACHECTIN TUMOR NECROSIS FACTOR PROTECTS MICE FROM LETHAL EFFECT OF ENDOTOXIN [J].
BEUTLER, B ;
MILSARK, IW ;
CERAMI, AC .
SCIENCE, 1985, 229 (4716) :869-871
[4]   ANTI-INTERFERON-GAMMA ANTIBODY PROTECTS MICE AGAINST THE GENERALIZED SHWARTZMAN REACTION [J].
BILLIAU, A ;
HEREMANS, H ;
VANDEKERCKHOVE, F ;
DILLEN, C .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1987, 17 (12) :1851-1854
[5]   THE PATHOGENESIS OF SEPSIS [J].
BONE, RC .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (06) :457-469
[6]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[7]   Sir Isaac Newton, sepsis, SIRS, and CARS [J].
Bone, RC .
CRITICAL CARE MEDICINE, 1996, 24 (07) :1125-1128
[8]   HIGH CIRCULATING LEVELS OF INTERLEUKIN-6 IN PATIENTS WITH SEPTIC SHOCK - EVOLUTION DURING SEPSIS, PROGNOSTIC VALUE, AND INTERPLAY WITH OTHER CYTOKINES [J].
CALANDRA, T ;
GERAIN, J ;
HEUMANN, D ;
BAUMGARTNER, JD ;
GLAUSER, MP .
AMERICAN JOURNAL OF MEDICINE, 1991, 91 (01) :23-29
[9]   CIRCULATING INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR IN SEPTIC SHOCK AND EXPERIMENTAL ENDOTOXIN FEVER [J].
CANNON, JG ;
TOMPKINS, RG ;
GELFAND, JA ;
MICHIE, HR ;
STANFORD, GG ;
VANDERMEER, JWM ;
ENDRES, S ;
LONNEMANN, G ;
CORSETTI, J ;
CHERNOW, B ;
WILMORE, DW ;
WOLFF, SM ;
BURKE, JF ;
DINARELLO, CA .
JOURNAL OF INFECTIOUS DISEASES, 1990, 161 (01) :79-84
[10]  
CEUPPENS JL, 1988, J IMMUNOL, V141, P3868